This inventor holds 2 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignee: Rohto Pharmaceutical Co., Ltd.. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2023
Title: Masayo Yumoto: Innovator in Mesenchymal Stem Cell Research
Introduction
Masayo Yumoto is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of regenerative medicine, particularly in the development of mesenchymal stem cells. Her innovative work has led to the filing of multiple patents that aim to enhance therapeutic effects against various diseases.
Latest Patents
Masayo Yumoto holds 2 patents related to ROR1-positive mesenchymal stem cells. Her latest patents include:
1. ROR1-positive mesenchymal stem cells and method for preparing the same.
2. Pharmaceutical composition containing ROR1-positive mesenchymal stem cells and method for preparing the same, and method for preventing or treating disease using ROR1-positive mesenchymal stem cells.
These inventions focus on providing novel mesenchymal stem cells that demonstrate superior therapeutic effects against various diseases. The ROR1-positive mesenchymal stem cells are characterized by specific cell surface markers and are derived from umbilical cord or adipose tissue.
Career Highlights
Masayo Yumoto is affiliated with Rohto Pharmaceutical Co., Ltd., where she continues her research and development efforts. Her work is pivotal in advancing the understanding and application of mesenchymal stem cells in medical treatments.
Collaborations
Some of her notable coworkers include Yoshifumi Ikeyama and Hiroyuki Nishida, who contribute to her research initiatives and collaborative projects.
Conclusion
Masayo Yumoto's innovative research in mesenchymal stem cells positions her as a key figure in regenerative medicine. Her patents reflect her commitment to improving therapeutic options for various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
